PreEclampsia
Our Dedication to Women and Families
LifeAssay Diagnostics won two Grand Challenges Grants from the Bill and Melinda Gates Foundation to develop and commercialize a low-cost PrCr urine dipstick to combat the devastating effects of Preeclampsia in developing countries.
The World Health Organization estimates that Preeclampsia/Eclampsia accounts for at least 16% of maternal deaths. Early identification of women at high risk for developing PE/E is key to linking them to proper health interventions to avoid complications and death.
The PrCr urine dipstick that has shown strong laboratory-based performance and high usability within ANC settings.
We have successfully placed PrCr tests in 225 clinics across Kenya, Zambia, Zimbabwe.
To learn more about our clinical data:
To learn more about our collaboration with PATH:
LifeAssay Diagnostics Test-it PrCr Urinalysis Dipstick Test
-
LifeAssay Diagnostics Test-itTM PrCr Urinalysis Dipstick Test
View PDF Development of new diagnostic tools to improve preeclampsia screening
-
Development of new diagnostic tools to improve preeclampsia screening
View PDFInstructions for use:
Estimate Proteinuria as follows:
